Trial Profile
A retrospective study to compare treatment persistence and adherence over one year in biologic naïve psoriatic arthritis (PsA) patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Oct 2017
Price :
$35
*
At a glance
- Drugs Apremilast (Primary)
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- 18 Oct 2017 New trial record
- 12 Oct 2017 Results presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research